title: Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing.
abstract: We have recently shown that valproate (VPA) decreases intracellular concentrations of inositol, like lithium but via a different mechanism, namely by inhibiting myo-inositol-1-phosphate (MIP) synthase. Valnoctamide (VCD) and valrocemide (VGD) are VPA derivatives which are anticonvulsants and have been shown in animal models to be significantly less teratogenic than VPA. We now show that 1 mM of either VCD or VGD drastically inhibits human brain crude homogenate MIP synthase activity. We studied the mechanism of the effect of VCD and found that it reduced the enzyme activity by an apparent competitive mode of inhibition at concentrations within the therapeutic range of VPA(Ki = 0.18 mM). We studied the behavioral effect of VGD and found that both lithium and VGD attenuated amphetamine-induced increase in rearing. These data support clinical study of these VPA-derivatives in bipolar disorder.
authors: Stanley Research Center, Ben-Gurion University of the Negev, PO Box 4600, Beersheva 84170, Israel.
authors: Galit
authors: G
authors: Shaltiel
authors: Shaltiel
authors: S
authors: Galit
authors: Shirley
authors: S
authors: Mark
authors: Mark
authors: M
authors: Shirley
authors: Ora
authors: O
authors: Kofman
authors: Kofman
authors: K
authors: Ora
authors: Robert H
authors: RH
authors: Belmaker
authors: Galila
authors: G
authors: Agam
authors: Agam
authors: A
authors: Galila
mesh_terms: D000577:Amides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D000661:Amphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D018692:Antimanic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D007279:Injections, Subcutaneous; D008094:Lithium / Q000494:pharmacology; D008297:Male; D007296:Myo-Inositol-1-Phosphate Synthase / Q000378:metabolism*; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000201:enzymology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014635:Valproic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*
chemical_list: D000577:Amides; D018692:Antimanic Agents; C045179:valnoctamide; D014635:Valproic Acid; C108894:TV 1901; D008094:Lithium; D000661:Amphetamine; D007296:Myo-Inositol-1-Phosphate Synthase; D005998:Glycine